Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?

Nivolumab Combined with Ipilimumab

Frontiers Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

ESMO 2019: Combination immunotherapy drugs offer new hope for melanoma patients - The Institute of Cancer Research, London

MBM - Melanoma Brain Metastases

Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy - Pires da Silva - 2020 - Cancer - Wiley Online Library